Loading clinical trials...
Loading clinical trials...
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Conditions
Interventions
zodasiran Injection
Placebo
Locations
22
United States
Research Site 7
Park Ridge, Illinois, United States
Research Site 2
New York, New York, United States
Research Site 1
Cincinnati, Ohio, United States
Research Site 14
Pittsburgh, Pennsylvania, United States
Research Site 13
Camperdown, New South Wales, Australia
Research Site 9
Saint Leonards, New South Wales, Australia
Start Date
June 17, 2025
Primary Completion Date
August 20, 2027
Completion Date
August 20, 2027
Last Updated
March 27, 2026
NCT07489209
NCT01109368
NCT06832371
NCT06723652
NCT03403374
NCT02651675
Lead Sponsor
Arrowhead Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions